key: cord-0022187-lzsip5ra authors: Boggi, Ugo; Vistoli, Fabio; Marchetti, Piero; Kandaswamy, Raja; Berney, Thierry title: First world consensus conference on pancreas transplantation: Part I—Methods and results of literature search date: 2021-07-29 journal: Am J Transplant DOI: 10.1111/ajt.16738 sha: 79723991ce816019e40060215b79a60444bc97ee doc_id: 22187 cord_uid: lzsip5ra Comprehensive evidence‐based guidelines for the practice of pancreas transplantation are yet to be established. The First World Consensus Conference on Pancreas Transplantation was convened for this purpose. A steering committee selected the participants and defined the questions to be addressed. A group of literature reviewers identified 597 studies to be included in summaries for guidelines production. Expert groups formulated the first draft of recommendations. Two rounds of discussion and voting occurred online, using the Delphi method (agreement rate ≥85%). After each round, critical responses of experts were reviewed, and recommendations were amended accordingly. Recommendations were finalized after live discussions. Each session was preceded by expert presentations and a summary of results of systematic literature review. Up to three voting rounds were allowed for each recommendation. To avoid potential conflicts of interest, deliberations on issues regarding the impact of pancreas transplantation on the management of diabetes were conducted by an independent jury. Recommendations on technical issues were determined by experts and validated using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument. Quality of evidence was assessed using the Scottish Intercollegiate Guidelines Network (SIGN) methodology. Each recommendation received a GRADE rating (Grading of Recommendations, Assessment, Development and Evaluations). This consensus conference does not aim to address any issues related to islet transplantation, either as a stand-alone therapy or as an alternative treatment option to pancreas transplantation. The consensus conference received no funds from private companies. Costs were largely covered by a main unrestricted grant from Fondazione Pisa (https://www.fonda zione pisa.it/). Additional financial support was obtained from Tuscany Region, University of Pisa, and Pisa University Hospital. There was also an economic contribution from registration fees. Industries were not involved in any step of the consensus, and no representative of commercial companies was involved in any committee, jury, expert panel, or literature review groups. No participant received an honorarium. Travel expenses were covered by modest preset amounts based on the distance to travel to the meeting. Lodging expenses were covered for all participants. The consensus involved a steering committee, a jury, a group of experts, a validation committee, and a group of literature reviewers. Miccoli) were also involved in supporting the work of the validation committee to ensure strict adherence to the Appraisal of Guidelines for Research and Evaluation II (AGREE II). 8 Through a series of online meetings and discussions, the steering committee identified the main topics that needed to be covered in the consensus and defined relevant questions for each topic. Questions, whenever possible, were proposed in PICO style (population, intervention, comparison, outcomes). A total of 12 main topics and 144 questions were defined. The 12 main topics were categorized in two key domains. First, the impact of SPK, PAK, and PTA on management of patients with diabetes (three topics for a total of 35 questions), as depicted in Table 2 . Second, technical issues related to practice of pancreas transplantation (nine topics for a total of 109 questions), as shown in Table 3 . To maintain objectivity, the overall impact of SPK, PAK, and PTA was defined by an independent jury and not by professionals holding potential interests in these treatments (e.g., pancreas transplant surgeons), while technical issues related to the practice of pancreas transplantation were evaluated by those who actually perform these procedures. The impact of SPK, PAK, and PTA on the management of patients with diabetes was assessed using the Zurich-Danish model (Table 4 ). 11 This model charges a jury with the duty to approve deliberations. The jury receives relevant information from expert groups, participates into audience discussions, asks questions to experts, and calls for an audience vote on proposed statements, but independently draws the final deliberations. Members of the jury have to be free from any potential conflict of interest with the topic to be evaluated. In contrast, recommendations on technical issues were approved by a panel of experts in pancreas transplantation and were validated by a distinct group of experts using the AGREE II instrument. 8 This consensus format has been used several times to address technical issues concerning surgical procedures, and results have been reported in high-impact journals. 12, 13 For each question, the following actions were undertaken: A systematic literature review. The search strategy followed guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions and was reported according to the Preferred Reporting Items for Systematic Reviews. 14, 15 Relevant studies were identified using PubMed, Embase, and Cochrane databases. Other studies identified by cross-referencing were also retrieved and reviewed. The following exclusion criteria were adopted: first, documents published in a format other than full-text peer-reviewed scientific article (e.g., abstracts from scientific meetings and book chapters); second, case reports; third, letters not containing original research data; fourth, articles not published in English; and fifth, articles from the same institution or research group. In this case, only the most recent contribution was considered, to avoid data overlap. Quality of evidence was assessed using the SIGN methodology. 9 All literature searches were conducted from January 1, 1967 to the closest possible date to the consensus conference in 2019. A summary of available studies. A sorted summary was prepared to answer each question and was included in evidence tables. Proposed recommendations were distributed online to all experts, for a first Delphi vote 16 using Google Modules. A space for feedback comments was also provided, so that if a recommendation was not approved (agreement rate ≥85%), the steering committee could draw a new proposal incorporating criticisms. Amended recommendations were then sent back to the experts for a second online Delphi vote. All responses were kept anonymous. All recommendations were discussed again at the consensus conference for final approval. The general structure of the consensus conference is summarized in Figure 1 3.11 Should kidneys be preferentially allocated to SPK recipients, when compared to recipients of kidney alone transplants? 3.12 Should kidneys be preferentially allocated to SPK recipients, when compared to recipients of kidney alone transplants with a PRA ≥80%? 3.13 Should kidneys be preferentially allocated to SPK recipients, when compared to recipients of other simultaneous transplants (i.e., liver-kidney, heartkidney, and lung-kidney)? 3.14 Are the results of SPK transplants in type 1 diabetic patients superior to the results of SPK transplants in type 2 diabetic patients so that a priority should be given to type 1 diabetics? 3.15 Are the results of SPK transplants in patients aged ≤50 years superior to the results of SPK in older patients so that a priority should be given to younger recipients? AJT BOGGI et al. 5.1 Is pancreas transplantation with bladder drainage associated with more frequent surgical complications when compared to pancreas transplantation with enteric drainage? 5.2 Is pancreas transplantation with bladder drainage associated with more frequent urologic and metabolic complications when compared to pancreas transplantation with enteric drainage? 5.3 Is SPK transplants with bladder drainage associated with superior immunologic outcomes when compared to SPK transplants with enteric drainage? 5.4 Is solitary pancreas transplants with bladder drainage associated with superior immunologic outcomes when compared to pancreas transplants with enteric drainage? 5.5 Is pancreas transplantation with portal venous drainage associated with higher rates of surgical complications when compared to pancreas transplantation with systemic venous drainage? 5.6 Is pancreas transplantation with portal venous drainage superior to pancreas transplantation with systemic venous drainage, with respect to immunologic outcome? 5.7 Is pancreas transplantation with portal venous drainage superior to pancreas transplantation with systemic venous drainage, with respect to metabolic parameters? 5.8 Is duodeno-duodenal anastomosis associated with more frequent surgical complications when compared to duodeno-jejunal anastomosis? 5.9 Is duodeno-duodenal anastomosis associated with improved immunologic outcome when compared to duodeno-jejunal anastomosis? 5.10 Is intraperitoneal pancreas placement associated with more frequent surgical complications when compared to retroperitoneal pancreas placement? 5.11 Is graft accessibility for percutaneous biopsy improved by retroperitoneal versus intraperitoneal pancreas graft placement? 6.1 Is steroid usage versus steroid avoidance associated with improved immunologic outcomes? 6.2 Is steroid usage versus early steroid withdrawal associated with improved immunologic outcomes? 6.3 Is steroid avoidance versus steroid usage associated with improved metabolic parameters? 6.4 Is early steroid withdrawal versus steroid maintenance associated with improved metabolic parameters? 6.5 Is induction versus no induction therapy associated with improved immunologic outcomes? 6.6 Is induction versus no induction therapy associated with more early complications? 6.7 Is induction versus no induction therapy associated with more oncologic complications? 6.8 Is induction therapy with depleting antibodies versus induction therapy with non-depleting antibodies associated with improved immunologic outcomes? 6.9 Is induction therapy with depleting antibodies versus induction therapy with non-depleting antibodies associated with more early complications? 6.10 Is induction therapy with depleting antibodies versus induction therapy with non-depleting antibodies associated with more oncologic complications? 6.11 Is CNI-free immunosuppression associated with inferior immunologic outcomes in pancreas transplantation when compared to CNI-including immunosuppression? 6.12 Is CNI-free immunosuppression associated with reduced toxicity in pancreas transplantation when compared to CNI-including immunosuppression? 6.13 Is tacrolimus superior to cyclosporine, with respect to immunologic outcomes, in SPK transplants? 6.14 Is tacrolimus superior to cyclosporine, with respect to immunologic outcomes, in solitary pancreas transplants? 6.15 Is once-a-day tacrolimus formulation superior to twice-a-day tacrolimus formulation in pancreas transplantation? 6.16 Is the use of mycophenolate formulations versus aziathioprine associated with improved immunologic outcomes in pancreas transplantation? 6.17 Is the use of mycophenolate formulations versus aziathioprine associated with more side effects in pancreas transplantation? 6.18 Is the use of m-TOR inhibitors versus mycophenolate formulations associated with improved immunologic outcomes in pancreas transplantation? 6.19 Is the use of mycophenolate formulations versus m-TOR inhibitors associated with more side effects in pancreas transplantation? 6.20 Is m-TOR-based immunosuppression versus CNI-based immunosuppression associated with improved immunologic outcomes in pancreas transplantation? 6.21 Is m-TOR-based immunosuppression versus CNI-based immunosuppression associated with more side effects in pancreas transplantation? 6.22 Is m-TOR-based immunosuppression versus CNI-based immunosuppression associated with increased formation of DSA in pancreas transplantation? 6.23 Is delayed introduction of m-TOR inhibitors better tolerated than immediate m-TOR-inhibitors introduction in pancreas transplantation? AJT BOGGI et al. Two online Delphi rounds were run among expert groups for all questions. The consensus meeting was held on two consecutive days (October 18 and 19, 2019) and was organized in sessions matching the predefined topics. Before each voting session, experts from working groups were asked to give presentations covering the questions to be addressed. After discussion of presentations, a summary of results of systematic literature review was also presented. Next, suggested recommendations were presented for audience discussion and vote (agreement rate ≥85%). Up to three voting rounds were allowed for each recommendation. Proportion of agreement was recorded for each question. Sensitization (or sensitized patient) was defined as the presence of circulating antibodies directed against human leukocyte antigens. 17 High sensitization (or highly sensitized patients) was defined as a panel reactive antibody >85%. 18 Obesity was defined according to World Health Organization (i.e., body mass index ≥30 kg/m 2 ). 19 Obesity classes (i.e., classes I-III), as well as ethnicity variations affecting obesity definition, were not considered because of lack of granular data in available literature. 8.1 Does surveillance evaluation of DSA levels improve the immunologic outcome of pancreas transplantation versus no surveillance serology? 8.2 Does surveillance pancreas biopsy improve the immunologic outcome of pancreas transplantation versus no surveillance biopsy in SPK transplants? 8.3 Does surveillance pancreas biopsy improve the immunologic outcome of pancreas transplantation versus no surveillance biopsy in solitary pancreas transplants? 8.4 In SPK transplants, is a first rejection episode best treated with steroid pulses or T cell-depleting antibodies? 8.5 In solitary pancreas transplant recipients, is a first rejection episode best treated with steroid pulses or T cell-depleting antibodies? 8.6 In SPK transplants, is a second rejection episode best treated with steroid pulses or T cell-depleting antibodies? 8.7 In solitary pancreas transplant recipients, is a second rejection episode best treated with steroid pulses or T cell-depleting antibodies? 8.8 What is the ideal treatment of antibody-mediated rejection in SPK transplants? 8.9 What is the ideal treatment of antibody-mediated rejection in solitary pancreas transplantation? 8.10 Autoimmune recurrence. How patients should be surveilled? Results of systematic literature reviews are provided in Figure 2 . Overall, 52 488 papers met the inclusion criteria in the 12 searches. After removal of duplications (−5341) and application of exclusion criteria (−42 399), and following review of titles and abstracts (−4151), 597 studies were included in summaries for guideline production. Literature search was finalized on July 20, 2019, using the terms "(simult*) and (pancr*) and (kidn* or ren*) and (transpl*)", revealing 1879 articles. After removal of duplication and application of exclusion criteria (−1306), and following review of titles and abstracts (−542), 31 studies were included in summaries for guideline production (Appendix 1). A. High quality of evidence Consistent evidence from well-performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk. B. Moderate quality of evidence Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate. Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain. Abbreviation: GRADE, grading of recommendations, assessment, development, and evaluations. High quality of evidence 1A Benefits clearly outweigh risk and burdens, or vice versa. 2A Benefits closely balanced with risks and burdens. Moderate quality of evidence 1B Benefits clearly outweigh risk and burdens, or vice versa. 2B Benefits closely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks, and burdens. 1C Benefits appear to outweigh risk and burdens, or vice versa. 2C Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens. Abbreviation: GRADE, grading of recommendations, assessment, development, and evaluations. AJT BOGGI et al. Literature search was finalized on September 9, 2019, using the terms Literature search was finalized on September 9, 2019, using the terms "pancrea*" (All Fields) and "transplan*" (All Fields) and Literature search was finalized on October 1, 2019, using the terms Literature Literature search was finalized on August 26, 2019, using the terms ("pancreas transplantation" [Majr]) and ("graft rejection" [Majr] or "protocol biopsy" or "donor specific antibodies" or "DSA" or "autoimmune recurrence" or "autoimmunity" or "diabetes recurrence"), revealing 399 articles. After removal of duplications and application of exclusion criteria (−293), and following review of titles and abstracts (−70), 36 studies were included in summaries for guideline production (Appendix 1). Two different literature reviews (on diabetic complications and quality of life) were performed to address follow-up. Both searches were finalized on July 31, 2019. The literature review on diabetic complications using the terms ("pancreas transplantation") and ("diabetic retinopathy" or "diabetic neuropathy" or "diabetic nephropathy" or "cardiovascular") revealed In the first 50+ years of pancreas transplantation, 1 with more than were produced and published, this meeting was indeed a workshop, rather than a formal consensus conference. 5, 6 The present conference was specifically designed to provide evidence-based recommendations for the practice of pancreas transplantation using specific, standardized, and validated methods. We also decided, for the first time ever, to define the impact of the main types of pancreas transplantation in the management of patients with diabetes. Information from this part of the consensus could be used for key decisions such as prioritization of patients for graft allocation and PTA, 9) . For the technical issues, we identified 109 questions that were categorized into nine main topics. After several online Delphi rounds 16 and exhaustive audience discussions and votings, recommendations were approved by a group of experts and eventually validated by an additional and independent group of experts using the AGREE II instrument. 8 Quality of evidence was assessed using the SIGN methodology, 9 and each recommendation was graded, 10 thus providing evidence-based guidelines for the practice of pancreas transplantation. Another key feature of our consensus conference is that we did not receive any funding or support from any commercial company. The successful organization of a conference free of any potential commercial bias was made possible by a 2-year fundraising effort to secure financial support from local institutions, mostly based on the commitment of local members of the steering committee. The degree of difficulty involved in bias-free fundraising may have been among the reasons why this type of a consensus conference had never been held in the past. Overall, over 52 000 publications were identified, leading to the definition of 597 full-text articles to be included in the quantitative analysis (Appendix 1). There were few prospective and randomized studies, mostly relating to immunosuppression. In contrast to most other areas of medicine, pancreas transplantation is not particularly suitable for prospective and randomized studies, considering that most institutions are low volume, that procedures are performed non-electively, and that patients with diabetes requiring a pancreas transplant are extremely complex. Additionally, for many years, the main questions in pancreas transplantation related to solving practical issues, such as surgical technique, preservation injury, and immunological graft failure, with proportionally less time devoted to welldesigned clinical studies. Having said that, as a pancreas transplant community, we should probably acknowledge that for too many years we have been more committed "to do" rather than to rigorously study pancreas transplantation and provide high levels of evidence. Now that the number of pancreas transplants is decreasing worldwide, 24 to design and conduct such studies would be even more complex. However, we should move into this direction, by collaborative efforts, and provide the missing pieces of evidence. Only these types of studies could better motivate our colleagues from medical disciplines to refer more patients for pancreas transplantation before the evolution of chronic complications of diabetes that can influence outcomes of the procedure or render it futile. Review of 50+ years of literature and extraction of data from several hundreds of articles was truly a major undertaking that could have intrinsic limitations and carry the risk of unintentional selection bias. Despite the creation of several dedicated teams for literature review, sharing and presentation of results of literature search, and online and in-person discussion of each statement, we acknowledge that some articles could have been missed. Additionally, Ovid/Medline was not included in the systematic reviews. Finally, only data from full peerreviewed manuscripts were considered, thus potentially missing data from abstracts that could have provided additional information. In conclusion, we have presented the methods and the results of literature search used for the First World Consensus Conference on Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy Update on pancreatic transplantation on the management of diabetes Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation Executive summary of IPITA-TTS opinion leaders report on the future of β-cell replacement Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop Evaluation of glucose metabolism after distal pancreatectomy according to the donor criteria of the living donor pancreas transplantation guidelines proposed by the Japanese Pancreas and Islet Transplantation Association AGREE next steps consortium. The global rating scale complements the AGREE II in advancing the quality of practice guidelines SIGN 50: a guideline developer's handbook An independent jury-based consensus conference model for the development of recommendations in medico-surgical practice The Miami international evidence-based guidelines on minimally invasive pancreas resection The Southampton consensus guidelines for laparoscopic liver surgery: from indication to implementation Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement An experimental application of the Delphi method to the use of experts Antibody-mediated rejection of solid-organ allografts Understanding immunological response to desensitisation strategies in highly sensitised potential kidney transplant patients Physical status: the use and interpretation of anthropometry Pancreas transplantation of US and Non-US cases from 2005 to 2014 as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) A randomized trial of closed-loop control in children with type 1 diabetes Home use of an artificial beta cell in type 1 diabetes Advances in β-cell replacement therapy for the treatment of type 1 diabetes Pancreas transplantation: an alarming crisis in confidence Berney T; the World Consensus Group on Pancreas Transplantation. First world consensus conference on pancreas transplantation: Part I-Methods and results of literature search Pancreas Transplantation. Results of the consensus conference are presented in detail in a separate manuscript in this issue of the journal. This consensus conference is dedicated to the loved memory of Mr.Fabrizio Iacopini, who made most of the local arrangements for the live sessions and unexpectedly died of COVID-19 before these proceedings could be published. The First World Consensus Conference had no funding from commercial companies. The conference received a main unrestricted grant from Fondazione Pisa. The following institutions also provided additional financial support: Regione Toscana, Università di Pisa, and Azienda Ospedaliero Universitaria Pisana. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. The data that support the findings of this study are available from the corresponding authors upon request.